The Dapagliflozin And Prevention of Adverse-Outcomes in Heart Failure (DAPA-HF) Trial: Baseline Characteristics

J.V. McMurray, John; L. DeMets, David; E. Inzucchi, Silvio; Køber, Lars; Kosiborod, Mikhail; Maria Langkilde, Anna; A. Martínez, Felipe; Bengtsson, Olof; Ponikowski, Piotr; S. Sabatine, Marc; Sjöstrand, Mikaela; D. Solomon, Scott

doi:10.1002/ejhf.1548

Public

The Dapagliflozin And Prevention of Adverse-Outcomes in Heart Failure (DAPA-HF) Trial: Baseline Characteristics

Published in European Journal of Heart Failure • Jul 15, 2019

Authors:

John J.V. McMurray

David L. DeMets

Silvio E. Inzucchi

Abstract

BACKGROUND: The aims of this study were to: (i) report the baseline characteristics of patients enrolled in the Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial, (ii) compare DAPA-HF patients to participants in contemporary heart failure (HF) registries and in other ...

Subject

Medicine

Heart failure

Dapagliflozin

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!